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ABSTRACT 
Focal segmental glomerulosclerosis (FSGS) is the consequence of a disease process that 
attacks the kidney's filtering system, causing serious scarring. More than half of FSGS 
patients develop chronic kidney failure within 10 years, ultimately requiring dialysis or renal 
transplantation. There are currently several genes known to cause the hereditary forms of 
FSGS (ACTN4, TRPC6, CD2AP, INF2, MYO1E and NPHS2). 
 
This study involves a large, unique, multigenerational Australian pedigree in which FSGS co-
segregates with first−degree heart block with apparent X−linked recessive inheritance. 
Through a classical combined approach of linkage and haplotype analysis, we identified a 
21.19 cM interval implicated on the X chromosome. We then used a whole exome 
sequencing approach to identify two mutated genes, NXF5 and ALG13, which are located 
within this linkage interval. The two mutations NXF5-R113W and ALG13-T141L segregated 
perfectly with the disease phenotype in the pedigree and were not found in a large healthy 
control cohort. Analysis using bioinformatics tools predicted the R113W mutation in the 
NXF5 gene to be deleterious and cellular studies support a role in the stability and 
localization of the protein suggesting a causative role of this mutation in these co-morbid 
disorders. Further studies are now required to determine the functional consequence of these 
novel mutations to development of FSGS and heart block in this pedigree and to determine 
whether these mutations have implications for more common forms of these diseases in the 
general population. 
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INTRODUCTION 
Focal and segmental glomerulosclerosis (FSGS) is a disease affecting the glomerular 
podocyte where the pathology is focal (not all glomeruli are involved), segmental (only part 
of a glomerulus is involved) with the presence of sclerosis of the glomerular capillary tuft 
that become more widespread with disease progression. It is clinically characterised by 
proteinuria and a progressive decline in renal function, eventually requiring renal replacement 
therapy (1-6). Onset may be congenital, usually in childhood, or may present in adulthood. 
FSGS accounts for 35% of all cases of idiopathic nephrotic syndrome and represents a final 
common pathway for a variety of other renal and systemic diseases (e.g. diabetic 
nephropathy) (1, 3, 5). 
 
Familial forms of FSGS are linked to a number of genetic loci (Supplementary Table 1). 
Mutations in some of these genes, for example NPHS1 and NPHS2 are also found in sporadic 
cases of FSGS (7). Many of the FSGS mutations have also been associated with syndromes 
involving non-renal tissues, for example nail-patella syndrome and Denys-Drash/Frasier 
syndrome. Genetic variation at the MYH9/APOL1 locus, which encodes the non-muscle 
myosin heavy chain and apoprotein L-1 (chromosome 22), has also been associated with an 
increased risk of hypertension and FSGS in African-Americans, but is not associated with 
familial FSGS (8-11). 
 
The mutated genes in the familial forms of FSGS encode podocyte proteins involved in the 
maintenance of glomerular slit diaphragms, which in turn, are responsible for holding back 
macromolecular structures like proteins within the vascular bed. The affected proteins include 
nephrin (NPHS1), a cation channel (TRPC6), α-actinin 4 (ACTN4), podocin (NPHS2), formin 
(INF2), an adaptor protein (CD2AP), a non muscle class I myosin (Myo1E), a RhoA-
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activated Rac1 GTPase-activating protein (ARHGAP24) and a phospholipase C (PLCE1) (12-
20) (supplementary Table 1). Some of the genes identified for familial cases of non-
syndromal FSGS may also be important in the more common, so called, “sporadic” versions 
of the disease (7-10). 
 
To date there are no reports in the literature of FSGS linkage to the X chromosome. We have 
identified a large Australian pedigree with FSGS and associated heart block which tends to 
transmit these two diseases in an X-linked recessive manner. FSGS and co-morbid heart 
block have not been previously observed for familial FSGS and there is no clinical or 
histological evidence of Fabry disease in this family. 
 
To date three genetic loci have been associated with progressive familial heart block 
(PFHB1A, PFHB1B and PFHB2) located on chromosomes 3p21, 19q13.2-q13.3 and 1q32.2-
q32.3 respectively. Mutations causing cardiac conduction defects were found in the genes 
SCN5A (PFHB1A) SCN1B and TRPM4 (PFHB1B), however no association with FSGS has 
been described at these loci (13, 21-23).  
 
We hypothesise that a novel mutation(s) in a gene(s) residing on the X chromosome is 
responsible for causing FSGS and co-morbid heart block in this affected pedigree. Here we 
provide a full description of this new phenotype and describe a combined approach of linkage 
and whole exome sequencing to identify the genetic mutation associated with these co-
segregating diseases in this Australian pedigree. 
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RESULTS 
Clinical Characteristics of FSGS Pedigree 
The pedigree (supplementary Fig. 1) came to our attention in 1998 after consultation with the 
proband (V:5(ID75)), who was diagnosed to have FSGS at the age of 32. At the age of 42, he 
developed complete heart block and required permanent pacemaker insertion. He was noted 
to be hypertensive at the age of 48 in the context of a family history of hypertension. Repeat 
renal biopsy at the age of 48, showed global sclerosis in 3/10 glomeruli. A further 3/10 
glomeruli showed segmental sclerosing lesions (Fig. 1). There was moderate tubular atrophy 
and interstitial fibrosis and a mild lymphocytic interstitial infiltrate. The interlobular arteries 
showed moderate arteriosclerosis. Immunofluorescence showed finely granular IgA 
deposition in the mesangium. Electron microscopy confirmed frequent small mesangial 
immune deposits. Renal function deteriorated and he started peritoneal dialysis at age 56.  An 
echocardiogram at age 57 was reported as showing mild concentric hypertrophy and a 
coronary angiogram was unremarkable. He was diagnosed with prostatic carcinoma at age 57 
and obstructive sleep apnoea consequent to obesity at the age of 59. He is currently 
maintained on haemodialysis. 
 
In the 6 generations starting from the mid-1800s, with the migration of a male from Britain, 
early death was a curse that followed the males of this family.  A total of 12 males are known 
to have developed progressive decline in renal function. The causes of premature death in 3 
males (ID1, ID8, and ID12) from 3 earlier generations who died in their second to fourth 
decade cannot be confirmed; however family histories suggest renal failure. Four of the 
affected males in more recent generations have died, one after pacemaker failure 
(IV:19(ID50)) and one five years after renal transplant (IV:26(ID62)). Two others had 
presumed renal failure (III:5(ID14) and III:7(ID16)) and one of these also had heart block 
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(III:5(ID14)) (history from family, death certificate or medical records). A histological 
diagnosis of the renal pathology is unavailable for these four affected males as they died prior 
to the development of renal biopsy as a routine clinical investigation in the regions they were 
residing. At present, there are five living males (V:1(ID69), V:5(ID75), V:14(ID85), 
V:24(ID105), VI:7(ID136)) with FSGS.  Biopsy data was available for 3 of the 5 living 
individuals for this study (V:1(ID69), V:5(ID75) and VI:7(ID136)).  
 
At least 6 males suffering from kidney failure are also known to have developed progressive 
cardiac conduction disorder (ID14, ID16, ID50, ID69, ID75 and ID85) which started with 
first degree heart block and eventually led to complete heart block. Three of these individuals 
are deceased and the surviving three have pacemakers. The two remaining individuals 
diagnosed with FSGS (ID105 and ID136) have not shown symptoms of heart block to date, 
however these individuals are the youngest affected males and may therefore still present 
with this co-morbidity.   
 
An additional living male (V:30(ID113)) presented with first-degree heart block and mild 
proteinuria at 20 years of age. This individual may either have a less severe phenotype or 
may be destined to proceed to the full syndrome with advancing age. The male-only 
presentation of FSGS traits and associated cardiac conduction disorder implies that an X-
linked recessive mode of transmission is acting in this pedigree. A summary of clinical 
characteristics of affected males is shown in Table 1. 
 
While female relatives are unaffected for the combined phenotypes of progressive FSGS and 
cardiac conduction disease, other potentially related clinical disorders have been observed in 
females of this pedigree. Two daughters (IV:7(ID34), IV:16(ID47)) of affected males have 
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had proteinuria with mild histological evidence of FSGS on renal biopsy, but have not 
developed progressive renal disease by their sixth decade. An additional two females 
(IV:23(ID55) and V:8(ID78)) have had proteinuria and haematuria for three decades without 
deterioration of renal function. Furthermore, pre-eclampsia has been reported in 10 women 
(IV:7(ID34), IV:16(ID47), IV:23(ID55), IV:24(ID59), V:10(ID80), V:11(ID82), V:13(ID84), 
V:16(ID88), VI:9(ID139), VI:12(ID142)), including the 2 presenting with mild non-
progressive FSGS, with no residual loss of renal function. 
 
Other conditions noted in this family include clear cell renal carcinoma in a male, transitional 
cell carcinoma of the renal pelvis in a female who is a putative obligate carrier under the X-
linked model (she also has an affected son), a malignant renal tumour in a young female, and 
a renal “cyst” in a putative carrier who had mild FSGS on renal biopsy in her third decade. A 
summary of the clinical phenotypes observed in living relatives are detailed in supplementary 
Table 2. 
 
This family appears to be unique. There have been no reports of any pedigree co-inheriting 
FSGS and progressive cardiac conduction disorder, nor have renal tumours been associated 
with either condition, other than a known increased risk of renal malignancy in patients with 
established renal failure. Moreover, there has not been a previous report of FSGS or 
associated disease being transmitted in an X-linked fashion.  
 
Linkage Analysis 
Only males exhibit the full form of both FSGS and first-degree heart block in this large 
multigenerational pedigree. The transmission pattern is suggestive of an X-linked mode of 
inheritance. To test this hypothesis, linkage analysis was performed using a high density 
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8 
(3.8cM) X-chromosomal scan. To prevent model misspecification, non-parametric linkage 
methods were employed. Two linkage scans were performed using subtly different 
phenotypic models. The results of multipoint linkage analysis are detailed in Fig. 2A. 
 
The first model included only those males who exhibited complete FSGS (Model 1). 
Significant evidence of linkage was detected at Xq markers, with a maximum LOD score of 
2.72 (p=2x10-4) observed at marker DXS1106. When the male individual presenting with a 
milder phenotype was included as affected (Model 2), the peak linkage signal at marker 
DXS1106 increased to a LOD score of 3.32 (p=5x10-5). The upper and lower limits of the 
95% confidence interval were at 118cM and 100cM, respectively. This result suggests the 
disease gene(s) must reside between markers DXS8077 and DXS8064, encompassing a 
21.19cM interval spanning Xq21.33 to Xq24. 
 
Co-segregation of the FSGS phenotype with the Xq haplotype is depicted in Fig. 2B. A 
predisposing haplotype has been inherited in all affected individuals. One unaffected 
individual (VI:2(ID137) also shares the predisposing haplotype. Subsequent to this analysis 
clinical information has become available showing that proteinuria has developed in this 
individual. Recombination events in 4 affected individuals (IV:13(ID50), V:1(ID69), 
V:2(ID75) and V:12(ID113)) reveal a shared disease haplotype comprised of 5 markers, 
spanning Xq22.1-23. 
 
In order to exclude linkage of autosomal loci to the phenotypes under investigation 20 
individuals (6 men from the youngest generations, with 3 affected and 3 unaffected, and 14 
females, including 11 obligate carriers and 3 unaffected) from the Australian pedigree were 
genotyped using the Affymetrix Genome-Wide Human SNP Array 6.0. While known FSGS 
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associated genes have been previously sequenced in this family this approach enabled 
exclusion of potentially causative insertions and deletions in these genes. Furthermore this 
approach confirmed the X-chromosome disease locus at the region between markers 
rs394127 and rs10521569, spanning a genomic region of approximately 16 Mb. 
 
This genomic region houses 145 genes (supplementary Fig. 2) including interesting 
candidates that are reported in supplementary Table 3. Recently the phenylalanine at codon 
222 of the COL4A5 gene located within this linkage interval was found mutated in a family 
showing X-linked glomerulopathy (24). Direct sequencing of all coding regions, including 
exon-intron boundaries, of the COL4A5 gene (and other candidates listed in Supplementary 
Table 3) did not identify any mutations in affected members of the pedigree, therefore 
excluding these genes as causative.    
 
FSGS gene identification strategy 
We performed whole-exome sequencing of two affected males from the Australian FSGS 
pedigree (ID69, and ID85). We adopted a prioritization scheme, well detailed in Table 2 to 
identify the pathogenic mutation in each individual, similar to the approach taken by other 
recent studies (25-27). In a first step we performed a thorough survey of all previously 
identified FSGS genes in order to definitively exclude their involvement in the disease 
phenotype. After filtering (see Table 2) we matched data from both individuals to obtain 
shared variants. Eighty autosomal non-synonymous coding variants were shared between the 
two samples. Only 40 of these variants were not found in the 1000 Genomes database and 
were confirmed by direct sequencing in the two patient samples.  
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None of the autosomal variants showed complete segregation with the disease in our family, 
adding support to the X-linked inheritance of the disease as demonstrated by linkage analysis 
(Table 2). 
 
Assuming that FSGS segregates as an X-linked disorder in our family we focused on X-
linked hemizygous variants that were not registered in dbSNPs or were not identified in our 6 
in-house exomes. We surveyed all genes of the X chromosome in each individual with 
particular attention on the 20 Mb region detected by linkage analysis (see Fig. 2A and 
supplementary Fig. 2). We obtained coverage of more than 40X for almost all exons, 
including exon-intron boundary and 5’ and 3’ untranslated regions (Supplementary Fig. 3). 
However, we found that the first exons in 12 different genes located in the linkage interval 
were not covered by a suitable number of sequences.  To ensure that these regions were fully 
interrogated we also analysed by direct Sanger sequencing to exclude the presence of variants 
in these exons. This sequencing approach identified four X-linked candidate gene mutations 
for ID69 and six X-linked candidate gene mutations for ID85. Among them, only mutations 
in two candidate genes, the Nuclear RNA Export Factor 5 (NXF5) gene and the Asparagine-
Linked Glycosylation 13 (ALG13) gene were common in the two individuals and were 
located in the linkage candidate region (Table 2). 
 
The inheritance of the R113W variant in the NXF5 gene and the T141L/ N121I variant in the 
ALG13 gene (T141L, isoform 2 NM_018466 and N121I isoform 3 NM_001039210) were 
examined by Sanger sequencing in DNA of 56 individuals of the family. This analysis 
confirmed that both variants segregated with the disease phenotype in the pedigree. We then 
checked these variants in the 1000 Genome database, and did not find any observations of 
them. In addition, we analysed 598 chromosomes from unrelated healthy controls from the 
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same geographical origin. Both the R113W variant of the NXF5 gene and the T141L/N121I 
variant in the ALG13 gene were absent in this cohort suggesting a role for either of these 
variants in the complex phenotype observed in this family. 
 
We then checked the linkage interval between the two candidate genes (NXF5 and ALG13) 
for SNP alleles that were not shared between the two affected samples. Approximately 1000 
SNPs were tested between the two genes using an Affymetrix chip assay and a deep 
sequencing approach; for these SNPs all alleles were shared between the two affected 
samples, providing evidence of a single haplotype spanning these two genes in the pedigree. 
 
Nuclear RNA export factor 5 (NXF5) gene 
Mutation analysis confirmed that the c.337C>T change in exon 7 of the NXF5 gene causes 
the R113W amino acid change (Fig. 3A). Most variants underlying rare Mendelian diseases 
either affect highly conserved sequences and/or are predicted to be deleterious. For this 
reason, we analysed the R113W variant with SIFT, PolyPhen2, PMut and Align GVGD 
software (http://sift.bii.a-star.edu.sg/www/SIFT_seq_submit2.html, 
http://genetics.bwh.harvard.edu/pph2/, http://mmb2.pcb.ub.es:8080/PMut/; 
http://agvgd.iarc.fr/agvgd_input.php) to confirm a deleterious effect of this variant. At this 
position (R113), only arginine (R), lysine (K) or glutamine (Q) are tolerated (supplementary 
Fig. 4).  PolyPhen-2, PMut and Align GVGD analysis supported the notion that this variant is 
“damaging” with a probability score of 0.67 (PolyPhen2) and prediction Class C65 (GV: 
0,00; GD: 101,29 Align GVGD). 
 
Three transcripts (ENST00000473265, ENST00000361708, and ENST00000537026) are 
described in the Ensembl genome browser (http://www.ensembl.org) for the human NXF5 
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gene, so to perform the expression profiling of these three transcripts of the NXF5 gene, we 
designed four sets of primers specific for each isoform. The expression profile was analysed 
using a panel of adult human tissues using a real time PCR assay. A different expression 
profile was observed for the different isoforms; significant expression was detected in brain, 
pancreas, kidney, testes, ovary and lung. A low expression level was detected in heart and no 
expression was detected in muscle (Fig. 3B). No difference of expression of NXF5 gene was 
observed in cDNA samples derived from patients blood (Fig. 3C). Direct sequencing of the 
PCR fragments showed that the mutated allele is expressed also in female carriers, suggesting 
that there is not skewed X inactivation (Fig. 3C). This data could explain the mild phenotype 
that we observed in female carriers.  
 
To assess the expression of this gene in podocytes an assay was designed to detect the Nxf7 
gene (the mouse homologue of NXF5) using RNA obtained from mouse podocytes as human 
podocyte tissue was unavailable.  Comparable levels of expression were observed for all 
tissues examined (Fig. 3D).  
 
The NXF5 gene belongs to the NXF gene family which, in humans, also includes the NXF1 
located on chromosome 11, as well as NXF2 and NXF3 genes clustered on Xq22.1. 
Evolutionary conservation analysis shows high similarity for these proteins. NXF3 seems to 
be the most ancient gene and, together with NXF1 and NXF2, is conserved in all mammals 
(Fig. 3E). Nxf7 is present only in mice and rats and was lost in primates, and NXF5 is a 
recently acquired gene present only in chimpanzees and humans. Some authors propose that 
the human NXF5 gene is the analogue of the mouse Nxf7 gene (28). Interestingly, the 
R113W amino acid change is conserved in all genes and all species except the NXF3 gene, in 
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which the arginine (R) is replaced with glutamine (Q) (Fig. 3E). However, glutamine is one 
of the three amino acids that SIFT predicts to be tolerated in this protein position. 
 
To assess if the NXF5-R113W mutation affects the stability and or the subcellular 
localization of the protein, HEK-293 and HK-2 human cell lines were transiently transfected 
with wt or mutant constructs (pcDNA3.1-NXF5-R113-HIS; pcDNA3.1-NXF5-W113-HIS; 
pEGFP-NXF5-C1-113R; pEGFP-NXF5-C1-113W). The GFP constructs gave a nonspecific 
pattern of expression resembling the empty pGFP-C1 vector, suggesting that this protein 
could be modified by digestion. Preliminary data suggest that the His-tagged NXF5 wt 
(113R) protein is localized in the nucleus and in the cytoplasm, including in the cellular 
processes and shows a higher level of expression then the mutated protein. The NXF5-113W 
protein localized mainly at the level of the nuclear membrane, suggesting that this mutation 
could affect the stability and the localization of the protein (Fig. 4A and B). Rhodamine 
phalloidin treatment of the cells, which stains the F-actin filaments, did not show differences 
in actin organization when the cells were transfected with wt or mutant proteins (Fig. 4A). 
 
Asparagine-Linked Glycosylation 13 (ALG13) gene 
In Ensembl, at least six transcripts of the ALG13 gene are reported to be protein-coding. The 
AC/TT nucleotide change identified in the examined family is located in an intronic region in 
isoform 1 (long isoform). In isoform 2 (NM_018466), the AC/TT variant is located in exon 6 
at position 421-422 and causes the amino acid change T141L, while in isoform 3 
(NM_001039210), the AC/TT variant is located in exon 6 at position 362-363 and causes the 
amino acid change N121I. Mutation analysis confirmed the segregation of this variant in all 
affected members of the FSGS family (Fig. 5A). The missense change affects highly 
evolutionarily conserved residues of ALG13 (Fig. 5B); however, SIFT software predicted a 
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tolerated effect for the T141L ALG13 variant, but the software was not able to predict any 
effect for the N121I variant.  Polyphen-2 and PMut analyses supported this by showing a 
very low probability of a damaging effect at this variant (P<0.05). However the Align GVGD 
software predicts a damaging effect of the ALG13-T141L variant (GV:0.00; GD: 92.35; 
Class C65). 
 
To perform expression profiling of the ALG13 gene, we analysed a panel of adult human 
tissues using a real-time PCR assay designed to specifically amplify the three ALG13 
isoforms. All isoforms were highly expressed in the ovary, kidney, pancreas, brain, testes, 
lung and heart. The short isoforms 2 and 3 were also highly expressed in, liver; and low 
expression levels were detected in muscle (Fig. 5C).  No difference of expression was 
observed for both isoforms in cDNA samples derived from patients’ blood (Fig. 5D). 
Podocyte expression was performed using RNAs from mouse tissue. Alg13 showed highest 
expression in the mouse podocyte from the panel (Fig. 5E).  
 
To assess any functional effect of the ALG13-T141L mutation human HEK-293 and HK-2 
cell lines were transiently transfected with wt or mutant constructs. Preliminary data does not 
show any difference between wt and mutant proteins in the level of expression and cytoplasm 
sub cellular localization suggesting that this mutation does not impair the stability or the 
localization of the protein and does not affect actin organization within the cell (data not 
shown). 
 
Overall, the complete absence of the R113W mutation in the NXF5 gene in the healthy 
control cohort coupled with the insilico prediction of a deleterious effect provides strong 
evidence that the R113W mutation in the NXF5 gene could be the causative disease mutation. 
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In addition however, the T141L/N121I mutation in the ALG13 gene cannot be ruled out 
completely despite three insilico predictions (SIFT PMut and PolyPhen2) that this mutation 
has a low probability of causing a damaging effect. Consequently this mutation may also 
contribute a small effect on disease phenotype. 
 
DISCUSSION 
Focal segmental glomerulosclerosis, one of the most common glomerulopathies, is typically 
marked by massive proteinuria and often associated with unremitting nephrotic syndrome and 
inexorable progression to end-stage kidney disease (2, 4, 6). Unfortunately, 
immunosuppressive therapy is frequently unsuccessful in the inherited forms of FSGS. 
Podocyte dysfunction is critical to the development of focal segmental glomerulosclerosis. 
Previously identified causal mutations in FSGS have shown the importance of a number of 
cytosolic genes encoding proteins that influence the podocyte cytoskeleton. (e.g., ACTN4, 
which encodes alpha-actinin-4; MYH9, which encodes myosin heavy chain 9; INF2, which 
encodes inverted formin 2; and MYO1E, a gene that encodes myosin 1E, a non-muscle class I 
myosin).  
 
Through the exome sequencing strategy, we identified a novel causative mutation (R113W) 
in the nuclear export factor 5 (NXF5) gene. In eukaryotes, the nuclear export of mRNA is 
mediated by nuclear export factor 1 (NXF1) receptors. Based on the extensive structural 
similarity of NXF family receptors, both within and across species, they are thought, like 
TAP/NXF1, to be involved in mRNA metabolism. For some of them, such activity has been 
confirmed by mRNA export assays (human NXF2), whereas the others (such as human 
NXF3) were inactive in these assays (29, 30).  
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In mice, Nxf2 and Nxf7 are analogues of human NXF2 and NXF5, respectively. Tretyakova 
et al. showed that Nxf2 has properties similar to those of TAP/NXF1; in contrast, Nxf7 has 
cytoplasmic RNA transport factor properties (28). The study further showed that Nxf7 binds 
to the light chain (L chain) of the brain-specific microtubule-associated protein MAP1B, 
which interacts with cytoplasmic microtubules and actin filaments. Subcellular localisation of 
mouse Nxf factors showed that GFP-Nxf7 was found only in small cytoplasmic foci, both in 
the cell body and in the neurites; it was excluded from the nucleus. GFP-Nxf7 formed mobile 
particles in the neurites, and a fraction of them moved unidirectionally. In both cell types, 
both anterograde and retrograde translocations were observed. The involvement of 
cytoskeletal components in Nxf7 particle motility was analysed with a short-duration 
colchicine treatment. This completely abolished the motility, indicating the involvement of 
microtubules. Our preliminary cellular studies show that the wt human NXF5 protein is 
localized in the nucleus and in the cytoplasm, including in the cellular processes, likes those 
observed for NXF2 (28). Moreover, the R113W mutation was observed to potentially affect 
the stability and the localization of the protein. Additional functional studies will be 
necessary to establish its role in the disease phenotype.  
 
A number of papers show that deletion or duplication in the NXF gene cluster, in particular, 
loss or overexpression of the NXF5 gene, cause severe mental retardation in men (31-34). 
Mutation analysis of the NXF5 gene and its neighbouring homologue, the NXF2 gene, did not 
identify causative mutations in 45 men with various forms of syndromic X-linked MR 
(XLMR) or in 70 patients with nonspecific XLMR (32). Our patients do not show any 
cognitive impairment; however, it is not rare that different mutations in the same gene cause 
different phenotype manifestations. Furthermore, genes expressed in different tissues, when 
mutated, show alteration only in specific tissues. Mutations involving WT1, a tumour 
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suppressor gene, lead to FSGS with multi-faceted clinical expressions such as Frasier 
syndrome (FSGS, XY hermaphroditism and high risk of gonadoblastoma) (35) and Bilateral 
Wilm’s tumour associated with FSGS (36). Abnormal splice variants of WT1 have also been 
associated with non-syndromic FSGS. Again, in an analogous manner, mutations affecting 
the Chromatin bundling protein (SMARCAL1) causes Schimke syndrome (immuno-osseous 
dysplasia) (37) which has FSGS as one of the components. 
 
It is interesting to note that a number of women within this pedigree also reported pre-
eclampsia. There are a number of publications in the literature that link pre-eclampsia with 
FSGS. Some have suggested that the occurrence of pre-eclampsia in families with FSGS may 
be indicative of being a carrier of FSGS genetic variants (38). Other detailed investigations of 
pre-eclampsia often identify FSGS lesions in the biopsies of patients. In this case there is 
significant debate regarding whether pre-eclampsia causes FSGS or whether FSGS is a 
predating condition (39). Nagai suggests that FSGS-like lesions occur in pre-eclampsia but 
may not be progressive as proteinuria resolves after pregnancy (40). Similarly Unverdi 
recently concluded that persistent proteinuria after delivery is a predictor of an underlying 
renal disease (41). The information we have available on the family shows a common 
occurrence of pre-eclampsia suggesting a genetic contributor. Thus while the occurrence of 
pre-eclampsia in this family may support the ‘carrier’ theory it is difficult to conclusively 
determine as not all women with pre-eclampsia have had sons and some women in earlier 
generations do not report pre-eclampsia. 
 
The significance of the mutation in the ALG13 gene, which is an N-linked glycosylase is 
unclear. It is tempting to postulate a role for this mutation with the presence of IgA mesangial 
deposits, as defective glycosylation of IgA molecule is postulated to be one of the 
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pathogenetic factors underlying IgA nephropathy (42). Again defective glycosylation of ion 
channel conductance proteins has been shown to underlie inherited cardiac conduction 
defects (43). However, preliminary studies in our lab do not suggest a functional significance 
for this mutation. 
 
The pathogenesis of the underlying cardiac conduction defect is a matter of speculation. 
Clinical observation suggests that the initial manifestation is first degree atrioventricular 
block with prolongation of P-R interval on the electrocardiogram. This appears to progress to 
third degree atrioventricular block with atrioventricular dissociation leading either to death in 
the earlier generations or needing cardiac pacemaker insertion in the current generations. One 
has to speculate that the same defects in the podocyte are likely to be the mechanisms leading 
to dysfunctional cardiac conduction, consequent to abnormalities in protein trafficking from 
the NXF5 gene mutation (44). 
 
Our expression studies, performed on RNA derived from patients’ blood, show that the 
mutation does not alter the expression or stability of the NXF5 transcript.  In addition the 
expression of the mutated allele in the female carriers demonstrates that there is no skewing 
of X inactivation, this may therefore explain the mild phenotype observed in the female 
carriers. 
 
We propose that the R113W mutation in the NXF5 gene identified in the examined FSGS 
family alters the biological function of the protein specifically in podocytes and in cardiac 
HIS-Purkinje system, producing an alteration in mRNA transport through cellular body and 
along the extensions. 
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MATERIALS AND METHODS 
Sample Ascertainment 
The study protocol was approved by the Griffith University Human Research Ethics 
Committee. The study complies with the Australian Health Ethics Committee (AHEC) and 
the National Statement on Ethical Conduct in Research Involving Humans (National Health 
and Medical and Medical Research Council) guidelines. All subjects gave informed consent 
prior to participation. In the case of minors, parental consent was obtained. A single, large, 
multigenerational Australian pedigree was utilised in this investigation and is depicted in 
supplementary Fig. 1. Clinical details were gathered by screening medical records (where 
available), patient interviews and telephone interviews with treating physicians. Cause of 
death of deceased individuals was obtained either through interview or examination of family 
records and death certificates where available. Histological details were obtained from 
hospital records where available. Phenotypic data were available for 89 individuals (26 males 
and 63 females) ranging in age from 4 to 94 years old. All individuals were of Caucasian 
ancestry. DNA was available for 75 individuals (20 males; 56 females). The sampled 
individuals included 4 severely affected males and an additional mildly affected male with 
first-degree heart block. 
 
DNA and Genotyping 
For all participants over the age of 18 years, DNA was extracted from peripheral blood by 
means of a QIAmp® DNA Maxi Kit (Qiagen). For participants aged under 18 years, DNA 
was collected from buccal swaps and isolated using a QIAmp® DNA Mini Kit (Qiagen). 
Genotyping was performed at the Australian Genome Research Facility (AGRF), Melbourne. 
A total of 47 highly polymorphic microsatellite markers with an average density of 3.8cM 
(minimum gap between markers 0.26cM; maximum gap between markers 11.586) were 
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genotyped across the entire X chromosome. Markers were amplified by PCR using 
fluorescently labelled primer pairs. All PCRs were performed in a total volume of 6uL, using 
a PTC-225 DNA Engine Tetra (MJ Research Inc, Waltham, MA, USA) under standard 
conditions. PCR products were multiplexed and electrophoresed on a 3730 DNA Analyzer 
(Applied Biosystems). Data was analysed using Applied Biosystems Genescan version 3.1 
and Genotyper version 2.1 software. 
 
We also used Affymetrix Genome-Wide Human SNP Array 6.0, containing more than 1.8 
million genetic markers, including more than 906,600 single nucleotide polymorphisms 
(SNPs) and more than 946,000 probes for the detection of copy number variation (CNV). 
Genotypes of each SNP were generated with Birdseed v2. Quantile normalisation was 
performed at probe level on the whole dataset (sample + 240 references). For each single 
marker (SNP or CNV) the ratio in log 2 scale between the sample and reference set was then 
calculated. 
 
Linkage Analysis 
Sex-averaged map positions were generated via locally weighted linear regression from 
NCBI build 35.1 physical map positions and the Rutgers genetic map (45). Pedstats version 
0.6.8 was used to detect typing errors (46). Erroneous genotypes were removed prior to 
analysis. Multipoint non-parametric linkage analysis was undertaken using MINX version 
1.1-alpha3 at 1cM increments (46). LOD scores were calculated according to the Kong and 
Cox exponential model (47). Haplotyping was performed in MINX and results were 
graphically displayed using Progeny version 5 
(http://www.progenygenetics.com/clinical/pedigree.html). MINX has a bit size limit of 24. 
Due to this computational constraint the original pedigree was trimmed to facilitate analysis. 
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The final trimmed pedigree structure was of 22 bit complexity (41 individuals; 22 males; 19 
females) and contained all necessary individuals to examine the hypothesis of an X-linked 
recessive disease locus. DNA was available for 26 (12 males; 14 females) pedigree members 
individuals. Two genetic models were examined. In model 1, a total of 10 males (5 with 
DNA available) were classed as affected. In model 2, the male individual presenting with a 
milder version of the phenotype (ID113) was also classed as affected (11 affected 
individuals; 6 with DNA available). 
 
Whole-exome sequencing strategy 
Genomic DNA samples from two affected males belonging to the Australian FSGS pedigree 
(ID69, and ID85) were assayed using the NimbleGen SeqCap EZ Exome™ capture kits 
(Roche) and resultant fragments sequenced with one lane per sample on an Illumina GAIIx 
(Illumina, San Diego, CA) with 90 bp paired-end reads. A total of 44,363,000 (ID69), and 
53,937,532 (ID85) paired-end reads were obtained and aligned to the human reference 
genome sequence (GRCh37/hg19) with MAQ7 and NextGENe software v2.00 with sequence 
condensation by consolidation (SoftGenetics, State College, PA). This approach resulted in a 
coverage of all exons (including exon-intron boundaries) and 5’ and 3’ untraslated regions of 
more than 40X. Supplementary Fig. 3 depicts coverage of part of the COL4A5 gene located 
in the linkage interval. Single nucleotide variants (SNVs) were called with MAQ and 
NextGENe. Small insertions and deletions were detected with NextGENe. Called SNVs were 
annotated with SeattleSeq Annotation and were filtered with dbSNP131. 
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Mutation analysis 
Validation and segregation analysis of the selected variants was performed by Sanger 
sequencing. PCR amplification and direct sequencing protocols have been previously 
described (48).  
 
Expression analysis 
NXF5 gene: To examine the tissue-specific expression pattern of the NXF5 gene, real-time 
PCR was performed on total RNAs from human adult tissues purchased from Stratagene, 
with the LightCycler system DNA Engine Opticon 2 (MJ Research). 1 g of total RNA was 
reverse transcribed with the Transcriptor HiFi cDNA Synthesis kit (Roche). qPCRs were 
performed as described in previous paper (49). The expressions were normalized versus 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) to account for differences in starting 
material and cDNA reaction efficiency. Agarose gel electrophoresis was performed to further 
confirm the specific PCR products. 
NXF5 transcript primers were: 
NXF5-1F 5’ TTACTGCGCCCTACTCTGTG 3’ 
NXF5-1R 5’ CCATGCAGTTTCTTGATT 3’ 
NXF5-2F 5’ CCCAGAGAGCCAGAGCCTAA 3’ 
NXF5-2R 5’ TGATCATGAGTGGGGCAAAT 3’ 
NXF5-3F 5’ AAGGATGGTCTCAGGGTTCT.3’ 
NXF5-3R 5’ AAGCCTGCACCATTTCCTGT 3’ 
NXF5-4F 5’ AAGGAAGGTGGTGGTGTTTG 3’ 
NXF5-3R 5’ AAGCCTGCACCATTTCCTGT 3’ 
The last primer was used both with the primer NXF5-3F and with the primer NXF5-4F. 
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The GAPDH primers were forward primer 5’AGCCACATCGCTCAGACAC 3’ and reverse 
primer 5’ GATCTCGCTCCTGGAAGATG 3’. 
 
ALG13 gene: 22 transcripts are reported in Ensembl database 
(http://www.ensembl.org/Homo_sapiens/Gene/Summary) for ALG13 gene, 6 of which are 
reported as protein coding. The AC/TT nucleotide change identified in our family is located 
in intronic region in transcript 1 (long isoform) and in exonic region in transcripts 2 and 3 
(short isoforms). We designed three different primer pairs, specific for the three isoforms to 
test their expression profile. The expression pattern was examined by real-time PCR 
performed on total RNAs from human adult tissues (Stratagene) as described before. GAPDH 
RNA was used as control. ALG13 primers were: 
ALG13isoform1F 5’ TGGAGACTCTGGAAAAAGGA 3’ 
ALG13isoform1R 5’ AGGAGCAGAAGCAATGGACT 3’ 
ALG13isoform2F 5’ CCTTGAAAGAAGACATTCAG 3’ 
ALG13isoform2R 5’ GCTGGCCAGGAGGATAACAT 3’ 
ALG13isoform3F 5’ CTCTGGATGTTTACAGGTGC 3’ 
The last primer was used with the primer ALG13isoform2R. 
 
Mouse podocyte preparation  
Kidneys were taken from mice aged between 7 to 10 days (max 15 days), and immediately 
immersed in culture medium (DMEM F12 medium supplemented with 10% FCS, 5 ug/ml 
transferrin, 10-7M hydrocortisone, 5 ng/ml sodium selenite, 0.12 U/ml insulin, 100 U/ml 
penicillin, 100 ug/ml streptomycin, 2 mM L-glutamine). The kidney was decapsulated, before 
passing through a series of sieves of decreasing mesh size: 100, 75, 50 and 36um. Glomeruli 
were collected from the top of the 36um sieves, centrifuged at 280 X g for 10 min at 4°C. The 
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pellet was re-suspended in the medium and further manually purified under a 
stereomicroscope by pipetting not only debris, but also the remaining glomeruli still 
surrounded by the Bowman’s capsule. The glomeruli were then seeded at 37°C, in 5% CO2 
humidified atmosphere, in culture flasks precoated with collagen type IV. After 7 - 10 days, 
glomeruli were ready to be detached by treatment with trypsin-EDTA, followed by filtering 
through the 36um mesh sieve to separate glomeruli from primary podocytes cells. When 
cultures were passaged, 90% of cells were identified as podocytes based on microscopy. 
These cells were seeded onto thermonax plastic collagen coverslips and characterized by 
immunocytochemistry (we used nephrin, podocin, cytokeratin, CD31, alpha-SMA, CD45).  
RNA preparation and RT-PCR assay were performed as already described (49), using the 
following mouse specific primers: 
Alg13F-mouse 5’ AGTCTGGAGAAAGGCAAACC 3’ 
Alg13R-mouse 5’AATCCAACAACTTTATCCAA 3’ 
Nxf7F  5’ TGTCCCAGACTTTCGCATTG 3’ 
Nxf7R  5’ GCAGCTTCTGTGATTTAGGA 3’ 
Gapdh-F 5’ TCCCTCAAGATTGTCAGCAA 3’ 
Gapdh-R 5’ AGATCCACAACGGATACATT 3’ 
 
Plasmids preparation, cell culture, and transfection 
The NXF5-337C (wt) construct was purchased from LifeSciences and the ALG13 cDNA 
clone (NM_018466) was synthesized at GeneCust Europe. These clones were used as 
template for the PCR reaction to generate the full length cDNA fragments to introduce in 
pcDNA3.1D/V5-His-Topo vector (Invitrogen) and pEGFP-C1 and pEGFP-N2 vectors 
(Clontech). The R113W (NXF5) and T141L (ALG13) mutagenesis were carried out by the 
Quick Change II XL site-directed mutagenesis technique according to the manufacturer’s 
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instructions (Stratagene). The whole coding sequences (NXF5 plus GFP, NXF5 plus His-Tag, 
ALG13 plus GFP and ALG13 plus His-Tag) of wild-type, and the mutant plasmids were 
sequenced to confirm the mutagenesis and to exclude undesired mutations. 
 
Human embryonic kidney (HEK) 293 cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% FBS (Invitrogen) and 2% L-glutamine in a 
humidified atmosphere of 5% CO2 at 37 °C. Human kidney-2 (HK-2), an immortalized 
proximal tubule epithelial cell line from normal adult human kidney, was cultured in 
DMEM/Ham's F12 supplemented with 5 μg/ml insulin, 0.02 μg/ml dexamethasone, 0.01 
μg/ml selenium, 0.05 μg/ml transferrin, 2 mM l-glutamine, 10% FBS, 100 U/ml penicillin, 
and 100 μg/ml streptomycin. The cells were maintained at 37°C under an atmosphere of 5% 
CO2/95% air.  
 
Transient transfections of plasmid DNAs in HEK-293 and HK-2 cells were accomplished 
using the Mirus bio (LLC) in Opti-MEM (Invitrogen) method according to the 
manufacturer’s instructions. Briefly, before transfection 4x105 cells were seeded in 24 wells 
plates on cover slips. After a 24 h incubation in growth medium, the cells were incubated in 
OPTI-MEM supplemented with 300ng of plasmid and 1 L of Mirus reagent. Each 
transfection was carried out in triplicate and repeated 4 times. Fixed cells were stained with 
mouse anti-His (Cell Signaling, 1:200) followed by goat anti-mouse IgG Texas Red 
conjugated secondary antibodies (Invitrogen, 1:200) (HEK-293 cells) and goat anti-mouse 
Oregon green 488 (Molecular probes, 1:200) (HK-2 cells). Rhodamine-phalloidin 
(Invitrogen) and DAPI (Invitogen) were used to visualise F-actin filaments and nuclei 
respectively. Fluorescence staining of human HK-2 and HEK-293 cells were visualised using 
inverted confocal laser microscopy. 
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Legends to Figures: 
Figure. 1 A: Renal Biopsy stained with showing a normal glomerulus from the 
proband (x 100) and B: A glomerulus showing Focal segmental Glomeruloslcerosis  
(x100). The affected glomerulus shows a sclerosed lobule between 3 ‘o’clock and 8 
‘o’clock positions. Silver stains the affected area black. C: Lower power view of 
another glomerulus (x 40) showing sclerosed segment between 6 ‘o’ clock and 11 ‘o’ 
clock  positions with mild tubular atrophy in the adjacent area. (Periodic acid Silver 
Methenamine stain. Courtesy of Dr. Leo Francis, Consultant Pathologist, Department 
of Anatomical Pathology, Royal Brisbane and Women's Hospital, Queensland Health, 
Herston, QLD, Australia). 
Figure. 2 A: Non-parametric linkage analysis results for the X chromosome (for 
Model 1 individual 12, generation 5 is unaffected; for Model 2 individual 12, 
generation 5 is affected). B: Chromosome Xq haplotypes in the trimmed pedigree. 
Markers are ordered centromere to telomere; DXS1217, DXS990, DXS8077, 
DXS8020, DXS1106, DXS1059, DXS8088, DXS8055, DXS6064 and DXS8067. 
Figure. 3 A: Mutation analysis NXF5 gene. Results of sequencing analysis and 
detection of mutation in exon 7 (c.337C>T, R113W). Arrowheads mark the site of 
base alternations. The sequences of an unaffected sample, a carrier and an affected 
subject from the FSGS-affected family are reported. The coding triplets and 
corresponding amino acids decided according to NXF5 cDNA are indicated. B: NXF5 
mRNA expression in human tissues. RT-PCR was performed using commercial 
mRNAs (Stratagene) of human adult tissues including heart, ovary, kidney, pancreas, 
liver, brain, testes, skeletal muscle, lung and heart. Four different set of primers 
designed on NXF5 alternative transcripts (see materials and methods) were used. 
Molecular weight markers 1kb Plus (Fermentas) (Marker) and the control lane for 
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GAPDH gene are shown. C: Expression profile of the NXF5 gene in RNA derived 
from blood of two female carriers, two affected males and two healthy samples (one 
male and one female) from the family. Primers used were NXF5-1F/NXF5-1R that 
include the R113W mutation. D: Expression profile of the Nxf7 gene in RNA derived 
from mouse tissues (total heart, podocytes, cortex, white matter and striatum). E: 
Comparative analysis of NXF1-NXF7 genes. Top: Evolutionary conservation of the 
arginine residue at position 113 indicated with an arrow. Bottom: phylogenetic tree. 
Figure. 4 A: Immunolocalization of NXF5 wt (NXF5-113R) and mutant (NXF5-
113W) proteins in HK-2 cells. NXF5 proteins were stained using anti-HIS 
antibody/Oregon green 488. F-actin fibres were stained with rhodamin phalloidin and 
nuclei were stained with DAPI. The localization of the NXF5 protein is indicated by 
green spots and is showed with white arrows. B: Immunolocalization of NXF5 wt and 
mutant proteins in HEK-293 cells using anti-HIS antibody/ Texas red.  
Figure. 5 A: Mutation analysis ALG13 gene: in isoform 2 (NM_018466), the AC/TT 
variant is located in exon 6 at position c.421-422 and causes the amino acid change 
T141L, while in isoform 3 (NM_001039210), the AC/TT variant is located in exon 6 
at position c.362-363 and causes the amino acid change N121I. Arrowheads mark the 
site of base alternations. The sequences of an unaffected sample, a carrier and an 
affected subject from the FSGS-affected family are reported. The coding triplets 
(bases underlined in black correspond to T141L change; bases underlined in red 
correspond to N121I change) and corresponding amino acids decided according to 
ALG13 cDNA are indicated. B: Evolutionary conservation of the AC>TT change in 
ALG13 gene. Top: in isoform 2 the amino acid threonine (T) at position 141 (reported 
in bold and underlined) is highly conserved in all species. Bottom: in isoform 3 the 
amino acid asparagine (N) at position 121 (reported in bold and underlined) is also 
 at G
riffith U
niversity on June 5, 2013
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
37 
 
highly conserved.   C: ALG13 mRNA expression in human tissues. RT-PCR was 
performed using commercial mRNAs (Stratagene) of human adult tissues including 
heart, ovary, kidney, pancreas, liver, brain, testes, skeletal muscle, lung and heart. 
Three different set of primers designed on the three alternative transcripts (indicated 
in figure) were used. Molecular weight markers (Marker) and the control lane for 
GAPDH gene are shown. D: Expression profile of the ALG13 gene in RNA derived 
from blood of two female carriers, two affected males and two healthy samples (one 
male and one female) from the family. Primers used were ALG13is2F/Alg13codR 
that include the T141L mutation. E: Expression profile of the Alg13 gene in RNA 
derived from mouse tissues (total heart, podocytes, cortex, white matter and striatum). 
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Table 1 Clinical characteristics of affected males 
Pedigree 
Position 
Pedigree 
ID 
FSGS or 
renal failure 
Cardiac Conduction 
disorder 
Deceased 
I:1 1 RF U Y 
III:1 8 RF U Y 
III:3 12 RF U Y 
III:5 14 RF PM Y 
III:7 16 RF U Y 
IV:19 50 RF PM Y 
IV:25 62 KT U Y 
V:1 69 FSGS KT PM - 
V:5 75 FSGS PM - 
V:14 85 KT PM - 
V:24 105 KT No - 
VI:7 136 FSGS No - 
V:30 113 P HB - 
RF: renal Failure, KT: kidney transplant, FSGS: confirmed by biopsy, P: proteinuria, 
U: unknown, PM: pacemaker, , HB: first degree heart block 
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Table 2 Summary of the whole exome sequencing of FSGS samples 
Data ID69 ID85 ID69+ID85 
Mapped Reads 39.320.410 (89%) 47.900.073 (89%)  
SNV 121.795 132.000  
dbSNPs 94.511 104.127  
coding variants 27.284 27.873  
Non synonym. (NS) 15.537 15921  
Frame-Shift 243 263  
NS after filter * 5767 5924  
Autosomal 5762 5918 80 
Aut+1000 genomes   40 
Aut+segregation   0 
X 4 6 2 
X+segregation 2 2 2 
X+segr.+delet. 1 1 1 
SNV: single nucleotide variation; *= non synonymous variants obtained after to 
filter with six in house genome (1 healthy individual and 5 individuals with 
unrelated diseases); Aut+1000 genomes= autosomal variants remaining after 
filtering with 1000 genome database; Aut+segregation= Autosomal variants 
remaining after segregation analysis in FSGS family; X+segregation= X variants 
remaining after segregation analysis; X+segr.+delet= X variants remaining after 
segregation analysis and after analysis of deleterious effect of the change with 
SIFT and Polyphen 2. 
 
 
Abbreviations: 
Focal segmental glomerulosclerosis (FSGS)  
Progressive Familial Heart Block (PFHB) 
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